Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $77.3 million.

  • Bicycle Therapeutics' Operating Expenses rose 1617.96% to $77.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $318.4 million, marking a year-over-year increase of 3643.45%. This contributed to the annual value of $245.1 million for FY2024, which is 1301.16% up from last year.
  • Bicycle Therapeutics' Operating Expenses amounted to $77.3 million in Q3 2025, which was up 1617.96% from $89.5 million recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year Operating Expenses high stood at $89.5 million for Q2 2025, and its period low was $17.8 million during Q1 2021.
  • Its 5-year average for Operating Expenses is $48.3 million, with a median of $51.2 million in 2024.
  • In the last 5 years, Bicycle Therapeutics' Operating Expenses surged by 7608.31% in 2022 and then soared by 275.19% in 2024.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' Operating Expenses stood at $21.8 million in 2021, then skyrocketed by 62.4% to $35.4 million in 2022, then skyrocketed by 68.28% to $59.6 million in 2023, then increased by 19.82% to $71.4 million in 2024, then grew by 8.29% to $77.3 million in 2025.
  • Its last three reported values are $77.3 million in Q3 2025, $89.5 million for Q2 2025, and $80.2 million during Q1 2025.